EU antitrust regulators have opened a full investigation into Dow Chemical and DuPont’s proposed $130 billion merger, saying the deal may reduce competition in crop protection, seeds and some petrochemicals.
The European Commission said the deal, which would create the world’s largest integrated crop protection and seeds company, may also hurt innovation.
“The livelihood of farmers depends on access to seeds and crop protection at competitive prices. We need to make sure that the proposed merger does not lead to higher prices or less innovation for these products,” European Competition Commissioner Margrethe Vestager said in a statement on Thursday.
The EU competition enforcer said concessions offered by the companies last month were insufficient to allay its concerns. Neither the Commission nor the companies provided details on the offer. The regulator delayed its final decision on the deal to Dec. 20.
Dow Chemical and DuPont said they would work constructively with the Commission to address its concerns and that they still expected the deal to close by the end of 2016.
Both companies are major suppliers of herbicides, insecticides, leading producers of gene editing technology as well as strong suppliers of specialty polyolefins which are widely used in packaging and adhesive applications.
The sector has seen a consolidation surge in recent months as companies bulk up to better compete with rivals.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas